Expanded Access Program
While participation in SolasCure’s clinical trials remains the preferred and most structured path for patients with chronic wounds to access Aurase Wound Gel, we understand that not all patients - particularly those with complex or life-threatening wound conditions - may be eligible for enrollment.
In certain circumstances, such as for serious and life-threatening conditions where no viable alternative treatments exist, SolasCure may provide access to our investigational therapies through our Expanded Access Program (EAP), also known as Compassionate Use.
How to Request Expanded Access?
Healthcare professionals who believe their patient may be eligible for and benefit from Expanded Access to Aurase Wound Gel are encouraged to contact us at EAP@solascure.com.
Please note that we review each request on a case-by-case basis, according to SolasCure’s internal policies, incorporating medical and scientific considerations and in line with legal and regulatory requirements. We aim to provide a response within two weeks of receiving a complete request. While SolasCure endeavours to support patients in need, requests for Expanded Access to Aurase Wound Gel remain at SolasCure’s discretion, are subject to product availability constraints, and access cannot be guaranteed.
Learn More About our Clinical Trials
We encourage patients and healthcare professionals to consider participation in our ongoing clinical trials whenever possible. For information on our active Phase II study in chronic venous leg ulcers, please visit:
At SolasCure we are committed to transforming how chronic wounds are treated. We work hand-in-hand with healthcare professionals to develop solutions that address real-world needs in advanced wound care and aim to improve patients’ quality of life. Our clinical development programs are rigorously designed to evaluate the safety and efficacy of our first investigational therapy, Aurase Wound Gel.